9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Estimated reading time: < 1 min

Condition: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface

Estimated Enrollment: 72

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Proportion of participants with adverse events,  Time to progression (TTP),  Overall Survival (OS), Progression-free Survival (PFS)

Interventions: DC vaccine, Celecoxib

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: February 18, 2019

Completion Date: February 18, 2019

Last  Posted Date: April 15, 2019

Location: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Website Link: https://ClinicalTrials.gov/show/NCT02151448

Was this article helpful?
Dislike 0